Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eosinophilic Gastroenteritis Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

NCT05757856
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NDX-3315, NDX-3324, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
NexEos Diagnostics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

NCT00358449
View directory record Official record
Conditions
Oesophagitis, Eosinophilic
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Not applicable Interventional

A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis

NCT03657771
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
DED, FREE
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Wilmington, Delaware • Orlando, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04322604
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions
lirentelimab (AK002), Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

NCT03191864
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo
Drug
Lead sponsor
Adare Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Chandler, Arizona • Tucson, Arizona • Sherwood, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 7, 2026, 9:21 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia

NCT01028235
View directory record Official record
Conditions
Dysphagia
Interventions
Not listed
Lead sponsor
San Antonio Uniformed Services Health Education Consortium
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 7, 2026, 9:21 PM EDT
Withdrawn Not applicable Interventional

Short Duration 6Fed Sponge For EoE Patients

NCT03354221
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Not applicable Interventional Results available

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
inhaled/swallowed budesonide, viscous/swallowed budesonide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

NCT05247866
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose, Dupilumab
Dietary Supplement · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Not applicable Interventional

A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

NCT05606705
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Baked Milk
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Pilot Study of Esocheck in Eosinophilic Esophagitis

NCT04311970
View directory record Official record
Conditions
Eosinophilic Esophagitis, Diagnoses Disease
Interventions
EsoCheck
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 7, 2026, 9:21 PM EDT
Not listed Phase 4 Interventional

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

NCT04149470
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omeprazole 20mg BID
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 7, 2026, 9:21 PM EDT
Terminated Not applicable Interventional

MRI to Assess Fibrosis in Eosinophilic Esophagitis Patients

NCT03446118
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
MRI to detect inflammation and fibrosis in subjects with EoE
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Placebo, lirentelimab (AK002)
Other · Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

NCT03029091
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 25 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
La Jolla, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

NCT01642212
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (MB-9), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 40 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

NCT01386112
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
EUR-1100, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 7, 2026, 9:21 PM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

NCT02778867
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)
Interventions
1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure), Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 7, 2026, 9:21 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Molecular Basis of Food Allergy

NCT01832324
View directory record Official record
Conditions
Food Allergy, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 65 Years
Enrollment
5,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 7, 2026, 9:21 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis

NCT05482256
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST), Colgate, High Resolution Esophageal Manometry (HREM)
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Dupilumab in Eosinophilic Gastritis

NCT03678545
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Dupilumab (blinded), Placebo (blinded)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 7, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Results available

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

NCT05444543
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone Propionate, Budesonide
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 7, 2026, 9:21 PM EDT